News coverage about ANI Pharmaceuticals (NASDAQ:ANIP) has been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. ANI Pharmaceuticals earned a news sentiment score of 0.08 on Accern’s scale. Accern also assigned headlines about the specialty pharmaceutical company an impact score of 45.899388113994 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the news headlines that may have effected Accern Sentiment’s rankings:

ANI Pharmaceuticals (NASDAQ:ANIP) opened at $69.41 on Friday. The stock has a market capitalization of $808.83, a PE ratio of 108.45 and a beta of 2.90. ANI Pharmaceuticals has a twelve month low of $42.23 and a twelve month high of $74.70. The company has a current ratio of 3.45, a quick ratio of 2.39 and a debt-to-equity ratio of 0.83.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.99 by $0.12. The company had revenue of $48.16 million for the quarter, compared to analyst estimates of $48.12 million. ANI Pharmaceuticals had a return on equity of 22.40% and a net margin of 4.45%. The business’s quarterly revenue was up 25.0% compared to the same quarter last year. During the same quarter last year, the company posted $1.09 earnings per share. sell-side analysts forecast that ANI Pharmaceuticals will post 3.59 EPS for the current year.

A number of analysts have weighed in on the company. ValuEngine upgraded ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, November 25th. BidaskClub upgraded ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday. Canaccord Genuity set a $75.00 price objective on ANI Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, December 9th. Zacks Investment Research lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, January 2nd. Finally, TheStreet raised ANI Pharmaceuticals from a “c+” rating to a “b” rating in a report on Thursday, November 16th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $71.00.

COPYRIGHT VIOLATION NOTICE: This report was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Insider Buying and Selling by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with's FREE daily email newsletter.